StreetInsider.com News Articles

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

Thu, 16 Jul 2026 06:00:00 -0400

VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026.

In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second quarter earnings conference call after release of its financial results. We look forward to providing an update following the expected closing of the proposed acquisition of Theravance

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

Thu, 16 Jul 2026 06:00:00 -0400

H.C. Wainwright Downgrades Theravance Biopharma (TBPH) to Neutral

Tue, 07 Jul 2026 07:37:18 -0400

H.C. Wainwright analyst Douglas Tsao downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $17.00 yesterday.

H.C. Wainwright Downgrades Theravance Biopharma (TBPH) to Neutral

Tue, 07 Jul 2026 07:37:18 -0400

H.C. Wainwright analyst Douglas Tsao downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $17.00 yesterday.

Zymeworks (ZYME) PT Raised to $31 at Truist Securities

Tue, 07 Jul 2026 07:09:49 -0400

Truist Securities analyst Gregory Renza raised the price target on Zymeworks (NASDAQ: ZYME) to $31.00 (from $28.00) while maintaining a Buy rating.

Form 4 Zymeworks Inc. For: Jul 06 Filed by: Hollywood Mark

Mon, 06 Jul 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260706/26736719.html

Form 4 Zymeworks Inc. For: Jul 06 Filed by: Hollywood Mark

Mon, 06 Jul 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260706/26736719.html

B. Riley: 'Aggressively Buying the ZYME Dip'

Mon, 29 Jun 2026 10:27:53 -0400

B. Riley: 'Aggressively Buying the ZYME Dip'.

The analyst comments "Aggressively Buying the ZYME Dip on Street Missing the Highly Accretive Nature of TBPH Acquisition; Best Outcome for Neutral-Rated TBPH Shareholders with Ampreloxetine CVR Optionality Built In This morning, ZYME announced a definitive agreement to acquire TBPH for $17.00/share in cash (i.e., ~$929M equity value) plus a non-tradeable CVR for 80% of any future ampreloxetine (amp) monetization within 10yrs (ZYME keeps 20%), funded by a $350M non-recourse note from OMERS Life Sciences secured solely by U.S. YUPELRI profit share, TBPH's ~$360M net cash at close, and $219M of ZYME cash. We

B. Riley: 'Aggressively Buying the ZYME Dip'

Mon, 29 Jun 2026 10:27:53 -0400

B. Riley: 'Aggressively Buying the ZYME Dip'.

BTIG Downgrades Theravance Biopharma (TBPH) to Neutral

Mon, 29 Jun 2026 09:20:33 -0400

BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

The analyst comments "Zymeworks (ZYME, Not Rated) has agreed to acquire TBPH for $17/sh, which is a 22% premium to TBPH's closing price on the day Phase 3 CYPRESS results were shared and a 10% premium to the volume-weighted average share price since this day (March 3, 2026). We do not anticipate any materially higher offers, and we expect this deal to close in 2H26, reflecting a culmination of TBPH's strategic review announced in March 2026. We believe ZYME makes sense as an acquirer given Yupelri's addition to

BTIG Downgrades Theravance Biopharma (TBPH) to Neutral

Mon, 29 Jun 2026 09:20:33 -0400

BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

BTIG Downgrades Theravance Biopharma (TBPH) to Neutral

Mon, 29 Jun 2026 09:20:33 -0400

BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

BTIG Downgrades Theravance Biopharma (TBPH) to Neutral

Mon, 29 Jun 2026 09:20:33 -0400

BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold

Mon, 29 Jun 2026 08:34:22 -0400

Jones Trading analyst Debanjana Chatterjee downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Hold.

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $17.63 yesterday.

Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold

Mon, 29 Jun 2026 08:34:22 -0400

Jones Trading analyst Debanjana Chatterjee downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Hold.

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $17.63 yesterday.

Form 8-K Zymeworks Inc. For: Jun 28

Mon, 29 Jun 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260629/26702043.html

Form 8-K Zymeworks Inc. For: Jun 28

Mon, 29 Jun 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260629/26702043.html

Zymeworks (ZYME) Reiterated at Buy by Stifel: 'Significantly Undervalued'

Mon, 29 Jun 2026 07:19:54 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $47.00 price target on Zymeworks (NASDAQ: ZYME).

The analyst commented, "We recently hosted a series of investor meetings with ZYME management – including Kenneth Galbraith (CEO), Kristin Stafford (CFO), and Shrinal Inamdar (IR). We continue to believe management’s differentiated approach to corporate strategy and capital allocation (balancing share repurchases, R&D investments, and royalty acquisition opportunities) represents a unique investment opportunity that defies traditional biotech dogma – i.e. the curation of long-duration cash flows and R&D-driven innovation cannot and should not co-exist under the same corporate umbrella. We believe visibility into the likely-significant

Zymeworks to buy Theravance Biopharma for $17 per share

Mon, 29 Jun 2026 06:00:25 -0400

Zymeworks Inc. (NASDAQ: ZYME) announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH) at $17.00 per share in cash, representing a total transaction value of approximately $929 million, subject to customary adjustments.

The acquisition adds YUPELRI (revefenacin), a nebulized long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease, to Zymeworks' portfolio. YUPELRI generated U.S. net sales of $266.6 million in 2025, a 12% increase over 2024. First-quarter 2026 U.S. net sales reached $62.4 million, up 7% from the same period in 2025.

The transaction will be financed through a $350 million non-recourse

Zymeworks to buy Theravance Biopharma for $17 per share

Mon, 29 Jun 2026 06:00:25 -0400

The transaction will be financed through a $350 million non-recourse

Zymeworks to Acquire Theravance Biopharma, Inc.

Mon, 29 Jun 2026 06:00:00 -0400

Acquisition adds YUPELRI^® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio
Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk
Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI^® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected growth
Transaction financed primarily by $350 million non-recourse note secured solely by U.S. YUPELRI^® profit share from OMERS Life Sciences, and

Zymeworks to Acquire Theravance Biopharma, Inc.

Mon, 29 Jun 2026 06:00:00 -0400

Acquisition adds YUPELRI^® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio
Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk
Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI^® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected growth
Transaction financed primarily by $350 million non-recourse note secured solely by U.S. YUPELRI^® profit share from OMERS Life Sciences, and

Zymeworks to Acquire Theravance Biopharma, Inc.

Mon, 29 Jun 2026 06:00:00 -0400

Acquisition adds YUPELRI^® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio
Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk
Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI^® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected growth
Transaction financed primarily by $350 million non-recourse note secured solely by U.S. YUPELRI^® profit share from OMERS Life Sciences, and

Zymeworks to Acquire Theravance Biopharma, Inc.

Mon, 29 Jun 2026 06:00:00 -0400

Acquisition adds YUPELRI^® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio
Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk
Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI^® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected growth
Transaction financed primarily by $350 million non-recourse note secured solely by U.S. YUPELRI^® profit share from OMERS Life Sciences, and

H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME)

Mon, 22 Jun 2026 06:59:59 -0400

H.C. Wainwright analyst Andrew Berens reiterated a Buy rating and $46.00 price target on Zymeworks (NASDAQ: ZYME).
The analyst commented: "At the recent ESMO Gynecological Cancers Congress, Zymeworks presented new dose-escalation results for its folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC), ZW191 (n=51; three median prior Rx), evaluating the relationship between FRα expression and treatment response. Per the poster presentation, ZW191 demonstrated a confirmed objective response rate (cORR) of 78.6% and 47.4% in response-evaluable FRα-positive (n=14; defined as a PS2+ score >75%) and FRα-negative (n=19; defined as a PS2+ score <75%) platinum-resistant ovarian cancer (PROC) patients, respectively, and a 40% cORR